StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Equities research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals stock opened at $0.65 on Tuesday. The business has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $0.76. Ayala Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $1.95.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.